Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Objective: Explore the cost-effectiveness of lifestyle interventions and metformin in reducing subsequent incidence of type 2 diabetes, both alone and in combination with a screening programme to identify high-risk individuals. Design: Systematic review of economic evaluations. Data sources and eligibility criteria: Database searches (Embase, Medline, PreMedline, NHS EED) and citation tracking identified economic evaluations of lifestyle interventions or metformin alone or in combination with screening programmes in people at high risk of developing diabetes. The International Society for Pharmaco-economics and Outcomes Research’s Questionnaire to Assess Relevance and Credibility of Modelling Studies for Informing Healthcare Decision Making was used to assess study quality. Results: 27 studies were included; all had evaluated lifestyle interventions and 12 also evaluated metformin. Primary studies exhibited considerable heterogeneity in definitions of pre-diabetes and intensity and duration of lifestyle programmes. Lifestyle programmes and metformin appeared to be cost effective in preventing diabetes in high-risk individuals (median incremental cost-effectiveness ratios of £7490/quality-adjusted life-year (QALY) and £8428/QALY, respectively) but economic estimates varied widely between studies. Intervention-only programmes were in general more cost effective than programmes that also included a screening component. The longer the period evaluated, the more cost-effective interventions appeared. In the few studies that evaluated other economic considerations, budget impact of prevention programmes was moderate (0.13%–0.2% of total healthcare budget), financial payoffs were delayed (by 9–14 years) and impact on incident cases of diabetes was limited (0.1%–1.6% reduction). There was insufficient evidence to answer the question of (1) whether lifestyle programmes are more cost effective than metformin or (2) whether low-intensity lifestyle interventions are more cost effective than the more intensive lifestyle programmes that were tested in trials. Conclusions: The economics of preventing diabetes are complex. There is some evidence that diabetes prevention programmes are cost effective, but the evidence base to date provides few clear answers regarding design of prevention programmes because of differences in denominator populations, definitions, interventions and modelling assumptions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“Type 2 diabetes develops as a result of genetic, environmental and behavioural factors, including sedentary lifestyle and energy-rich, nutrient-poor diet, both of which predispose to obesity.(5) Diabetes takes a significant toll on health budgets around the world, accounting for 5%–20% of total healthcare expenditure…”
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Decision Modelling For Health Economic Evaluation
Briggs, A., Claxton, K., & Sculpher, M. (2006) · doi:10.1093/oso/9780198526629.001.0001 · Cited by 3,153
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
The Finnish Diabetes Prevention Study (DPS)
Lindström, J., Louheranta, A., Mannelin, M., Rastas, M., Salminen, V., Eriksson, J., Uusitupa, M., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3230 · Cited by 1,848
Eriksson, K. F., & Lindg�rde, F. (1991) · Diabetologia · doi:10.1007/bf00400196 · Cited by 1,092
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
International Diabetes Federation: a consensus on Type 2 diabetes prevention
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02157.x · Cited by 778
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males
Kosaka, K., Noda, M., & Kuzuya, T. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.06.010 · Cited by 656
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
Ali, M. K., Echouffo-Tcheugui, J. B., & Williamson, D. F. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1009 · Cited by 594 · cited 2×
“However, reviews of community translations of the USDPP trial showed that while these translational programmes cost less to implement they were also less effective.(19) 20 The modelling studies based on the USDPP trial data may therefore not be relevant comparators for a USDPP-based community programme.”
Risk models and scores for type 2 diabetes: systematic review
Noble, D., Mathur, R., Dent, T., Meads, C., & Greenhalgh, T. (2011) · BMJ · doi:10.1136/bmj.d7163 · Cited by 551 · cited 1×
“Most commonly, screening blood tests are offered to people identified as at high risk of developing diabetes based on demographic variables (eg, age, ethnicity), survey questions (eg, family history of diabetes, personal history of gestational diabetes) or biomarkers (eg, body mass index (BMI), blood pressure), typica…”
Self-citationCost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Balk, E. M., Earley, A., Raman, G., Avendano, E. A., Pittas, A. G., & Remington, P. L. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0452 · Cited by 371
Ramachandran, A., Snehalatha, C., Ram, J., Selvam, S., Simon, M., Nanditha, A., Shetty, A. S., Godsland, I. F., Chaturvedi, N., Majeed, A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70067-6 · Cited by 330
Saito, T. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.275 · Cited by 277
Islet amyloid polypeptide: structure, function, and pathophysiology
Akter, R., Cao, P., Noor, H., Ridgway, Z., Tu, L.-H., Wang, H., Wong, A. G., Zhang, X., Abedini, A., Schmidt, A. M., et al. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2798269 · Cited by 273
Morris, D. H., Khunti, K., Achana, F., Srinivasan, B., Gray, L. J., Davies, M. J., & Webb, D. (2013) · Diabetologia · doi:10.1007/s00125-013-2902-4 · Cited by 229
Ockene, I. S., Tellez, T. L., Rosal, M. C., Reed, G. W., Mordes, J., Merriam, P. A., Olendzki, B. C., Handelman, G., Nicolosi, R., & Ma, Y. (2012) · American Journal of Public Health · doi:10.2105/ajph.2011.300357 · Cited by 201
Bhopal, R. S., Douglas, A., Wallia, S., Forbes, J. F., Lean, M. E. J., Gill, J. M. R., McKnight, J. A., Sattar, N., Sheikh, A., Wild, S. H., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70204-3 · Cited by 149
Diabetes Prevention Program Research Group (2015) · Diabetes Care · doi:10.2337/dc14-0886 · Cited by 139
Lifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk
Jacobs-van der Bruggen, M. A. M., Bos, G., Bemelmans, W. J., Hoogenveen, R. T., Vijgen, S. M., & Baan, C. A. (2007) · Diabetes Care · doi:10.2337/dc06-0690 · Cited by 137
Palmer, A. J., Roze, S., Valentine, W. J., Spinas, G. A., Shaw, J. E., & Zimmet, P. Z. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90029-x · Cited by 128 · cited 2×
“…studies evaluating metformin, 2 studies concluded metformin was cost saving from a health system perspective, 40 46 1 study concluded metformin was cost saving from a health system perspective in some countries but not others 47 and 2 concluded metformin was cost saving from a societal perspective.”
The Healthy Living Partnerships to Prevent Diabetes Study
Katula, J. A., Vitolins, M. Z., Morgan, T. M., Lawlor, M. S., Blackwell, C. S., Isom, S. P., Pedley, C. F., & Goff, D. C. (2013) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.12.015 · Cited by 127
Davies, M. J., Gray, L. J., Troughton, J., Gray, A., Tuomilehto, J., Farooqi, A., Khunti, K., & Yates, T. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2015.12.012 · Cited by 123
Zhuo, X., Zhang, P., Gregg, E. W., Barker, L., Hoerger, T. J., Pearson-Clarke, T., & Albright, A. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1115 · Cited by 82
Value of Lifestyle Intervention to Prevent Diabetes and Sequelae
Dall, T. M., Storm, M. V., Semilla, A. P., Wintfeld, N., O’Grady, M., & Venkat Narayan, K. M. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.10.003 · Cited by 53
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021
Ogurtsova, K., Guariguata, L., Barengo, N. C., Ruiz, P. L.-D., Sacre, J. W., Karuranga, S., Sun, H., Boyko, E. J., & Magliano, D. J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109118 · Cited by 952
Healthy Eating and Active Lifestyles: Best Practices in Public Health
OECD (2022) · OECD eBooks · doi:10.1787/40f65568-en · Cited by 276
The metabolic syndrome – What is it and how should it be managed?
Nilsson, P. M., Tuomilehto, J., & Rydén, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319886404 · Cited by 272
Zhou, X., Siegel, K. R., Ng, B. P., Jawanda, S., Proia, K. K., Zhang, X., Albright, A. L., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dci20-0018 · Cited by 173
“A recent study reviewed the CE of both lifestyle andmetformin for T2D prevention among high-risk individuals but did not include population-based approaches (18).”
Background
Metadata
- Authors
- Roberts, S., Barry, E., Craig, D., Airoldi, M., Bevan, G., & Greenhalgh, T.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-11
- Volume
- 7
- Issue
- 11
- Pages
- e017184
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2755687550
- Cited by
- 122
- References
- 30
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.